Am J Transplant, Volume 21, Suppl 3 Archives - Page 129 of 139 - ATC Abstracts

2021 American Transplant Congress
Development Following Pediatric Kidney Transplantation
L. Pape, J. Prüfe
Pediatrics II, University Hospital of Essen, Essen, Germany
*Purpose: Kidney transplantation for children suffering CKD5 has been established in Germany approximately 50 years ago. While in the early decades the focus was merely…
2021 American Transplant Congress
Utility of Donor-Derived Cell Free DNA for Detecting ABMR in Patients With AT1R Antibodies
S. Kant¹, D. Kumar², I. Moinuddin², T. Alhamad³, M. Haris³, J. Gray⁴, B. Dale⁴, M. Bettinotti¹, D. C. Brennan¹
¹Johns Hopkins University School of Medicine, Baltimore, MD, ²VCU, Richmond, VA, ³Wash Univ, St. Louis, MO, ⁴CareDx, Brisbane, CA
*Purpose: The presence of angiotensin II type 1 receptor (AT1R) antibodies is associated with non-HLA active antibody mediated rejection (ABMR). The frequent co-existence of negative…
2021 American Transplant Congress
Psmp is Discriminative for Chronic Active Antibody-Mediated Rejection and Predicts Graft Risk After Kidney Transplantation
Y. Fu, P. Zhan
Tianjin First Central Hospital, Tianjin, China
*Purpose: Chronic active antibody-mediated rejection (c-aABMR) is an intermediate process in the development of chronic antibody-mediated rejection (c-ABMR), a key problem in the long-term failure…
2021 American Transplant Congress
Association of Donor-Derived Cell-Free DNA with Severity of Interstitial Fibrosis and Cortical Atrophy Lesions Following Kidney Transplantation
L. Bu¹, E. Stites², V. Bowers³, T. Alhamad⁴, J. S. Bromberg⁵, G. Gupta⁶, I. Moinuddin⁶, S. Ghosh⁷, W. Tian⁷, A. Pai⁸, S. Anand⁹
¹University of Minnesota, Minneapolis, MN, ²University of Colorado, Aurora, CO, ³Tampa General Hospital, Tampa, FL, ⁴Washington University in St. Louis, St. Louis, MO, ⁵University of Maryland School of Medicine, Baltimore, MD, ⁶Virginia Commonwealth University, Richmond, VA, ⁷CareDx, Brisbane, CA, ⁸University of Texas McGovern Medical School, Houston, TX, ⁹Intermountain Medical Center, Murray, UT
*Purpose: The most common cause of kidney transplant (KT) failure is the poorly characterized histopathologic entity “interstitial fibrosis and tubular atrophy” (IFTA). There are no…
2021 American Transplant Congress
Subjective Cognition Among Liver Transplant Recipients
D. Ko¹, M. S. Dietrich², K. A. Gifford³, S. H. Ridner²
¹School of Nursing, Northeastern University, Boston, MA, ²School of Nursing, Vanderbilt University, Nashville, TN, ³Department of Neurology, Vanderbilt University Medical Center, Nashville, TN
*Purpose: Regular assessment of cognition is highly suggested to facilitate the early detection and treatment of cognitive impairment in the liver transplant (LT) population. While…
2021 American Transplant Congress
Algorithms to Identify Alcoholic Hepatitis Hospitalizations in Patients with Cirrhosis
S. Panchal¹, D. Kaplan², D. Goldberg³, N. Mahmud²
¹Medicine, Hospital of the University of Pennsylvania, Philadelphia, PA, ²Gastroenterology, Hospital of the University of Pennsylvania, Philadelphia, PA, ³Gastroenterology, University of Miami Miller School of Medicine, Miami, FL
*Purpose: With the rising proportion of patients receiving liver transplantation for alcoholic hepatitis, it is important to identify methods of ascertaining hospitalizations with alcoholic hepatitis…
2021 American Transplant Congress
Implementation of an Alcohol Screening Program Identifies Active Pre-transplant Drinking and Allows Engagement in Chemical Dependency Treatment
N. Lim¹, T. Leventhal¹, M. Thomson¹, M. Hassan¹, J. Thompson¹, S. Chinnakotla², V. Kirchner², T. Pruett², R. Kandaswamy², V. Humphreville², A. Adams², J. Lake¹
¹Division of Gastroenterology, Hepatology and Nutrition, University of Minnesota, Minneapolis, MN, ²Division of Transplantation, University of Minnesota, Minneapolis, MN
*Purpose: Alcohol (ETOH) is an important cause of cirrhosis in the US today. Screening patients for ETOH use prior to LT is important to identify…
2021 American Transplant Congress
Liver Transplantation Following Checkpoint Inhibitor Therapy – Timing is Everything
G. T. Schnickel¹, J. Parekh¹, Y. Kono², J. Berumen¹, V. Ajmeera², K. Mekeel¹
¹Division of Transplant and Hepatobiliary Surgery, Department of Surgery, University of California San Diego, San Diego, CA, ²Division of Gastroenterology, Department of Medicine, University of California San Diego, San Diego, CA
*Purpose: Use of checkpoint inhibitors (CPI) prior to liver transplantation has not been well studied and limited case reports describe a risk of early graft…
2021 American Transplant Congress
Utilization of Pre-Procurement Donor Liver Biopsy in Donation-after-circulatory-Death Liver Transplantation
A. C. Bolognese¹, N. Neidlinger¹, C. Sparks², A. Schneider², A. M. D'Alessandro¹, D. P. Foley¹
¹Department of Surgery, Division of Transplantation, University of Wisconsin School of Medicine and Public Health, Madison, WI, ²UW Organ and Tissue Donation, Madison, WI
*Purpose: Careful selection of suitable DCD donor livers is critical to obtain optimal transplant outcomes. In order to identify potentially suitable livers prior to DCD…
2021 American Transplant Congress
The Survival Benefits of Using Marginal Allografts in Liver Transplantation
T. H. Malik¹, E. L. Godfrey¹, A. Rana²
¹Baylor College of Medicine, Houston, TX, ²Department of Abdominal Transplantation, Baylor College of Medicine, Houston, TX
*Purpose: Our study assessed whether using marginal allografts at initial time of listing provided similar or greater survival benefit versus waiting on the transplant waitlist…